Myriad Genetics, Inc. (MYGN) Given Average Rating of “Hold” by Analysts

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have been given a consensus rating of “Hold” by the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $28.90.

A number of equities analysts have issued reports on MYGN shares. Cowen reaffirmed a “hold” rating and set a $25.00 price objective on shares of Myriad Genetics in a report on Sunday, September 17th. Stephens reissued an “overweight” rating and issued a $40.00 price target (up from $36.00) on shares of Myriad Genetics in a report on Friday, September 22nd. Leerink Swann reissued a “market perform” rating and issued a $31.00 price target on shares of Myriad Genetics in a report on Monday, October 2nd. Morgan Stanley reissued an “underweight” rating and issued a $24.00 price target (up from $17.00) on shares of Myriad Genetics in a report on Friday, October 6th. Finally, Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price target on the stock in a report on Tuesday, October 17th.

In other Myriad Genetics news, Director Walter Phd Gilbert sold 7,500 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $33.19, for a total transaction of $248,925.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Alexander Ford sold 3,031 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $31.64, for a total transaction of $95,900.84. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,531 shares of company stock worth $545,826. Insiders own 6.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CS Mckee LP lifted its holdings in Myriad Genetics by 0.3% during the second quarter. CS Mckee LP now owns 30,000 shares of the company’s stock valued at $775,000 after purchasing an additional 100 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in Myriad Genetics by 1.0% during the second quarter. Public Employees Retirement System of Ohio now owns 143,036 shares of the company’s stock valued at $3,696,000 after purchasing an additional 1,480 shares during the last quarter. TrimTabs Asset Management LLC lifted its holdings in Myriad Genetics by 17.2% during the third quarter. TrimTabs Asset Management LLC now owns 11,798 shares of the company’s stock valued at $427,000 after purchasing an additional 1,728 shares during the last quarter. Riverhead Capital Management LLC lifted its holdings in Myriad Genetics by 80.9% during the second quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock valued at $107,000 after purchasing an additional 1,861 shares during the last quarter. Finally, Stifel Financial Corp lifted its holdings in Myriad Genetics by 3.6% during the third quarter. Stifel Financial Corp now owns 54,408 shares of the company’s stock valued at $1,968,000 after purchasing an additional 1,900 shares during the last quarter.

Myriad Genetics (MYGN) opened at $35.53 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. The stock has a market cap of $2,460.00, a price-to-earnings ratio of 24.01, a price-to-earnings-growth ratio of 2.21 and a beta of 0.24. Myriad Genetics has a fifty-two week low of $15.15 and a fifty-two week high of $37.30.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, November 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.05. The firm had revenue of $190.20 million for the quarter, compared to the consensus estimate of $183.52 million. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.23 EPS. sell-side analysts anticipate that Myriad Genetics will post 1.05 earnings per share for the current fiscal year.

WARNING: “Myriad Genetics, Inc. (MYGN) Given Average Rating of “Hold” by Analysts” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://stocknewstimes.com/2018/01/12/myriad-genetics-inc-mygn-given-average-rating-of-hold-by-analysts.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply